A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2− advanced breast cancer. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Jerusalem, Guy; Bachelot, Thomas; Barrios, Carlos; Neven, Patrick; Di Leo, Angelo; Janni, Wolfgang; de Boer, Richard
• Is Part Of: Cancer treatment reviews. Volume 41:Issue 2(2015)
• Page Start: 94
• Page End: 104
• Publication Date: 2015-02
• Subjects: Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2014.12.011
• Languages: English
• ISSNs: 0305-7372

Abstract

<abstract xml:lang="en" abstract-type="author-highlights" id="ab005"> <title id="st075">Highlights</title> <sec> <p id="sp0005"> <list id="l0005"> <list-item id="o0005"> <label></label> <p id="p0190">Progression on endocrine therapy (ET) is problematic in HR⁺ advanced breast cancer.</p> </list-item> <list-item id="o0010"> <label></label> <p id="p0195">Targeting compensatory growth pathways may enhance or extend endocrine sensitivity.</p> </list-item> <list-item id="o0015"> <label></label> <p id="p0200">Benefits of dual targeting are most evident after disease progression on initial ET.</p> </list-item> </list> </p> </sec> </abstract>